Loading stock data…
Integra LifeSciences Holdings C (IART)
$16.26-0.46 (-2.75%)
Market ClosedLast close Sep 8
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Integra LifeSciences Holdings Corporation in the Healthcare sector is trading at $16.26 with a market capitalization of $1.4B. Wall Street consensus targets $19.56 (9 analysts), implying a +20.3% move over the next 12 months. The stock is currently 21% below its 52-week high of $20.49, remaining 17.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $418.76M↑ | $391.92M↓ | $434.93M↑ | $402.06M↓ | $415.61M |
| Gross Profit | $219.74M↑ | $216.98M↓ | $220.87M↑ | $206.99M↓ | $209.33M |
| Operating Income | $19.29M↑ | $11.47M↓ | $23.04M↑ | $11.76M↑ | -$1.31M |
| Net Income | $4.48M↑ | -$4.62M↓ | -$1.70M↑ | -$5.40M↑ | -$484.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Sur...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.69%
Volume
Today's trading volume
621,212
Recent News
3 Cash-Producing Stocks That Fall Short
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.